Many people with COPD can control their symptoms by using inhaled medicines each day. But inhaled medicines may not offer enough relief for people who also have high levels of a type of white ...

Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester, discusses insights from the FLAME trial analysis and the ICS-RECODE meta-analysis.

Some of the most popular asthma and COPD inhalers are pictured. AstraZeneca's Symbicort, on the far right, uses greenhouse gases as its propellant. | Alamy Total revenue for the drug fell some 7 ...

With COPD, you have lung damage that worsens over time. Trelegy Ellipta does not come as a generic drug. Trelegy Ellipta comes in a dry powder inhaler. Each active ingredient in Trelegy Ellipta ...

Chronic obstructive pulmonary disease is a serious, progressive illness that hits the homeless and underinsured the hardest.

While people with asthma or chronic obstructive pulmonary disease (COPD) can experience worse symptoms due to climate change, many of the medications they’re prescribed also contribute to ...

Respiratory Inhaler Devices MarketThe global respiratory inhaler devices market, valued at USD 37,258.5 million in 2023, is projected to grow at a compound annual growth rate (CAGR) of 4.90%, reaching ...

AstraZeneca recently announced the completion of clinical studies for a next-generation propellant (NGP) version of its chronic obstructive pulmonary disease (COPD) inhaler, Breztri. This new ...

This week Bobbi Conner talks with Dr. Charlie Strange about the diagnosis and treatment of COPD. Dr. Strange is a professor ...

Currently, COPD-marketed therapy leaders include GSK’s Trelegy Ellipta, which is set to grow in sales to $2.16bn by 2033.

AIIMS has reported a increase in cases related to respiratory issues, particularly asthma and COPD allegedly due to Delhi air ...